New therapeutic avenues in autoimmunity

Research in Immunology

Volumn 147, Issue 6, 1996, Pages 361-376

  Amital, H ^a,b   Swissa, M ^a,b   Bar Dayan, Y ^a,b   Buskila, D ^c   Shoenfeld, Y ^a,b  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

autoimmunity; cytokines; dietary modifications; idiotypes; intravenous immunoglobulin; MHC blocking peptides; oral tolerance; T cell receptors; therapy; times and trends

Indexed keywords

AUTOANTIGEN; CYTOKINE; FISH OIL; GAMMA INTERFERON ANTIBODY; IMMUNOGLOBULIN; IMMUNOGLOBULIN IDIOTYPE; INTERLEUKIN 1; INTERLEUKIN 10 ANTIBODY; INTERLEUKIN 2; INTERLEUKIN 6 ANTIBODY; MONOCLONAL ANTIBODY; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG;

AUTOIMMUNITY; DIET; DRUG THERAPY; ETIOLOGY; HUMAN; IMMUNOTHERAPY; INTRAVENOUS DRUG ADMINISTRATION; MAJOR HISTOCOMPATIBILITY COMPLEX; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; THERAPY;

EID: 0029833059     PISSN: 09232494     EISSN: None     Source Type: Journal    
DOI: 10.1016/0923-2494(96)82045-1     Document Type: Article

References (150)

1. [1] Ben-Yehuda, O., Tomer, Y. & Shoenfeld, Y. (1988), Advances in therapy of autoimmune disease. Semin. Arthritis Rheum., 17, 206-220.
2. [2] Romagnani, S. (1995), Biology of human TH1 and TH2 cells. J. Clin. Immunol., 15, 121-129.
3. [3] Fruet, P., Sheela, R. & Pelletier, L. (1995), Th1 and Th2 cells in autoimmunity. Clin. Exp. Immunol., 101 (Suppl.), 9-12.
4. [4] Fossati, L., Takahashi, S., Merino, R. et al. (1993), MRL-lpr\lpr substrain with a limited expansion of lpr double-negative T cells and a reduced autoimmune syndrome. Int. Immunol., 5, 525-532.
5. [5] Vreugdenhil, G., Lowenberg, B., Van Ejik, H.G. et al. (1992), Tumor necrosis factor alpha is associated with disease activity and the degree of anemia in patients with rheumatoid arthritis. Eur. J. Clin. Invest., 22, 488-493.
6. [6] Husby, G. & Williams, R.C., Jr. (1988), Synovial localization of tumor necrosis factor in patients with rheumatoid arthritis. J. Autoimmun., 1, 363-371.
7. [7] Piguet, P.F., Grau, G.E., Vesin, C. et al. (1992), Evolution of collagen arthritis in mice is arrested by treatment with anti-tumor necrosis factor (TNF) antibody or recombinant soluble TNF receptor. Immunology, 77, 510-514.
8. [8] Elliott, M.J., Maini, R.N., Feldman, M. et al. (1993), Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor-α. Arthritis Rheum., 36, 1681-1691.
9. [9] Elliot, M.J., Maini, R.N., Feldman, M. et al. (1994), Repeated therapy with monoclonal antibody to tumor necrosis factor-α (cA2) in patients with rheumatoid arthritis. Lancet, 344, 1125-1127.
10. [10] Wendling, D., Racadot, E. & Wijdenes, J. (1993), Treatment of severe rheumatoid arthritis by anti-interleukin-6 monoclonal antibody. J. Rheumatol., 20, 259-262.
11. [11] Dinarello, C.A. & Thompson, R.C. (1991), Blocking IL-1: interleukin-1 receptor antagonist in vivo and in vitro. Immunol. Today, 11, 404-410.
12. [12] Amital, H., Blank, M. & Shoenfeld, Y. (1996), Augmentation of experimental anti-DNA idiotype induced lupus by IFN-γ administration.
13. [13] Bach, J.F. (1995), Anti-gamma IFN (IFN-γ) monoclonal antibodies, in "Monoclonal antibodies and peptide therapy in autoimmune diseases." (Bach, J.F.) (pp. 319-328). Marcelk Dekker, Inc. New-York.
14. [14] Ishida, H., Muchamuel, T., Sakaguchi, S. et al. (1994), Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB-W mice. J. Exp. Med., 179, 305-310.
15. [15] Lloerente, L., Zou, W., Levy, Y. et al. (1995), Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus. J. Exp. Med., 181, 839-844.
16. [16] Cavallo, M.G., Pozzilli, P. & Thopre, R. (1994), Cytokines and autoimmunity. Clin. Exp. Immunol., 96, 1-7.
17. [17] Dayer-Metroz, M.D., Wollheim, C.B., Seckinger, P. et al. (1989), A natural interleukin 1 (IL-1) inhibitor counteracts the inhibitory effect of IL-1 on insulin production in cultured rat pancreatic islets. J. Autoimmun., 2, 163-171.
18. [18] Eisenberg, S.P., Evans, R.J., Arend O.P. et al. (1990), Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist. Nature (Lond.), 343, 341-346.
19. [19] Allison, J., Malcolm, I., Chosich, N. et al. (1992), Inflammation but not autoimmunity occurs in transgenic mice expressing constitutive IL-2 in islet β cells. Eur. J. Immunol., 22, 1115-1121.
20. [20] Kelley, V.E., Gaulton, G.N., Hattori, M. et al. (1988), Anti-interleukin-2 receptor antibody suppresses murine diabetic and lupus nephritis. J. Immunol., 140, 59-61.
21. [21] Nicoletti, F., Meroni, P.L., Landolfo, S. et al. (1990), Prevention of diabetes in BB/Wor rats treated with monoclonal antibodies to IFN gamma. Lancet, 336, 319.
22. [22] Campbell, I.L., Kay, T.W.H., Oxbrow, L. et al. (1991), Essential role of IFN-gamma and interleukin-6 in autoimmune insulin-dependent diabetes in NOD/Wehi mice. J. Clin. Invest., 87, 739-742.
23. [23] Trebleau, S., Germann, T., Gately, M.K. et al. (1995), The role of IL-12 in the induction of organ-specific autoimmune diseases. Immunol. Today, 16, 383-386.
24. [24] Katz, J.D., Beniost, C. & Mathis, D. (1995), T helper subsets in insulin-dependent diabetes. Science, 268, 1185-1188.
25. [25] Kennedy, M.K., Torrance, D.S., Picha, K.S. et al. (1992), Analysis of cytokine mRNA expression in the central nervous system of mice with experimental allergic encephalomyelitis reveals that IL-10 mRNA expression correlates with recovery. J. Immunol., 149, 2496-2505.
26. [26] Leonard, J.P., Waldburger, K.E. & Goldman, S.J. (1995), Prevention of experimental autoimmune encephalomyelitis by antibodies against interleukin 12. J. Exp. Med., 181, 381-386.
27. [27] Cash, E., Minty, A., Ferrara, P., Caput, D. et al. (1994), Macrophage-inactivating IL-13 suppresses experimental autoimmune encephalomyelitis in rats. J. Immunol., 153, 4258-4267.
28. [28] Ferguson, K.M., Osawa, H., Diamantstein, T. et al. (1988), Treatment with anti-interleukin-2 receptor antibody protects from passive but not active adjuvant arthritis. Int. Immunopharmacol., 4, 29-33.
29. [29] Jacobs, C.A., Baker, P.E., Roux, E.R. et al. (1991), Experimental autoimmune encephalomyelitis is exacerbated by IL-1α and suppressed by soluble IL-1 receptor. J. Immunol., 146, 2983-2989.
30. [30] Lebsack, M.E., Paul, C.C. & Martindale, J.J. (1993), A dose and regimen ranging study of IL-1 receptor antagonist in patients with rheumatoid arthritis. Arthritis Rheum., 36, S39.
31. [31] Panitch, H.S., Hirsch, R.L., Schindler, J. et al. (1987), Treatment of multiple sclerosis with IFN-γ. Exacerbations associated with activation of the immune system. Neurology, 37, 1097-1102.
32. [32] Batra, J.K., Fitzgerald, D., Gatdy, M. et al. (1990), Anti-Tac (Fv)-DE40, a single chain antibody pseudomonas fusion protein directed at interleukin-2 receptor-bearing cells. J. Biol. Chem., 265, 15198-15202.
33. [33] Korak, R.W., Atcher, R.W., Gansow, O.A. et al. (1986), Bismuth-212 labeled anti-Tac monoclonal antibody: alpha particle-emitting radionuclides as modalities for radioimmunotherapy. Proc. Natl. Acad. Sci. USA, 83, 474-478.
34. [34] Case, J.P., Lorberboum-Galski, H., Lafyatis, R. et al. (1989), Chimeric cytotoxin IL-2 PE40 delays and mitigates adjuvant-induced arthritis in rats. Proc. Natl. Acad. Sci. USA, 80, 287-291.
35. [35] Olshes, S., Sandvig, K., Petersen, O.W. et al. (1989), Immunotoxins: entry into cells and mechanism of action. Immunol. Today, 10, 291-295.
36. [36] Williams, R.O., Mansom, L.J., Feldman, M. et al. (1994), Synergy between anti-CD4 and anti-TNF in the amelioration of established collagen-induced arthritis. Proc. Natl. Acad. Sci. USA, 91, 2762-2766.
37. [37] Finck, B.K., Chan, B. & Wofsy, D. (1994), Interleukin 6 promotes murine lupus in NZB/NZW F1 mice. J. Clin. Invest., 94, 585-591.
38. 4 treatment of MRL/lpr mice ameliorates immunopathology and lymphoproliferation but fails to suppress rheumatoid factor production. Clin. Immunol. Immunopathol., 61, 421-435.
39. [39] Tomer, Y., Blank, M. & Shoenfeld, Y. (1994), Suppression of experimental antiphospholipid syndrome and systemic lupus erythematosus in mice by anti-CD4 monoclonal antibodies. Arthritis Rheum., 37, 1236-1244.
40. [40] Mulchings, P.R., O'Reilly, L., Paish, N.M. et al. (1992), The use of a non-depleting anti-CD4 monoclonal antibody to re-establish tolerance to β cells in NOD mice. Eur. J. Immunol., 22, 1913-1918.
41. [41] Cush, J. & Lipski, P.E. (1991), Cellular basis of rheumatoid arthritis. Clin. Orthop., 265, 9-22.
42. [42] Issacs, J.D., Manna, V.K., Hazleman, B.L. et al. (1993), CAMPATH™-1H in RA - A new study of multiple IV dosing. Arthritis Rheum., 36, S40.
43. [43] Emmirch, F., Sculze-Koops, H. & Burmester, G. (1994), Anti-CD4 and other antibodies to cell-surface antigens for therapy, in "Immunopharmacology of joints and connective tissue." (pp. 87-117). Academic Press Ltd.
44. [44] Kalden, J.R. (1994), Biologic agents in the therapy of inflammatory theumatic diseases, including therapeutic antibodies, cytokines, and cytokine antagonists. Curr. Opin. Rheumatol., 6, 281-286.
45. [45] Kalden, J.R. (1994), Anti-CD4 treatment of patients with rheumatoid arthritis. Is there a place for this treatment principle in RA ? Clin. Exp. Rheumatol., 12, S67-S69.
46. [46] Emmrich, J., Seyfanth, M., Fleig, W.E. et al. (1991), Treatment of inflammatory bowel disease with anti-CD4 monoclonal antibody. Lancet, 338, 570-571.
47. [47] Finkel, T.H., Kubo, R.T. & Cambier, J.C. (1991), T-cell development and transmembrane signaling: Changing biological responses through an unchanging receptor. Immunol. Today, 12, 79-85.
48. [48] Chatenoud, L. (1994), Use of CD3 antibodies in transplantation and autoimmune diseases. Transplant. Proc., 26, 3191-3193.
49. [49] Hughes, C., Wolos, J.A. & Giannini, E.H. (1994), Induction of T helper cell hyporesponsiveness in an experimental model of autoimmunity by using non-mitogenic anti-CD3 monoclonal antibody. J. Immunol., 153, 3319-3125.
50. [50] Chatenoud, L., Thervet, E., Primo, J. et al. (1993), Anti-CD3 antibody induces long-term remission of overt autoimmunity in non-obese diabetic mice. Proc. Natl. Acad. Sci. USA, 91, 123-127.
51. [51] Youinou, P., Buskila, D., MacKenzie, L.E. et al. (1993), CD5-positive B cells and disease, in "Natural autoantibodies" (Shoenfeld, Y. & Isenberg, D.A.) (pp. 143-165). CRC Press, Inc. Boca Raton.
52. [52] Davis, M.M. (1988), Molecular genetics of T cell antigen receptors. Hosp. Pract., 23, 157-163.
53. [53] Plater-Zyberk, C., Taylor, P.C., Blaylock, M.G. et al. (1994), Anti-CD5 therapy decreases severity of established disease in collagen type-II-induced arthritis in DBA/1 mice. Clin. Exp. Immunol., 98, 442-447.
54. [54] Caperton, E., Byers, V., Shephard, J. et al. (1989), Treatment of refractory rheumatoid arthritis (RA) with anti-lymphocyte immunotoxin (Abstract). Arthritis Rheum., 32, 130.
55. [55] Cannon, G.W., Marble, D.A., Griffiths, M.M. et al. (1995), Immunologic assessment during treatment of rheumatoid arthritis with anti-CD5 immunoconjugate. J. Rheumatol., 22, 207-213.
56. [56] Stafford, F.J., Fleischer, T.A., Lee, G. et al. (1994), A pilot study of anti-CD5 ricin A chain immunoconjugate in systemic lupus erythematosus. J. Rheumatol., 21, 2068-2070.
57. [57] Poulter, L.W., Duke, O., Panayi, G.S. et al. (1985), Activated T-lymphocytes of the synovial membrane in rheumatoid arthritis and other arthropathies. Scand. J. Immunol., 22, 683-690.
58. [58] Kirkham, B., Chikanza, I., Pitzalis, C. et al. (1988), Response to monoclonal CD7 antibody in rheumatoid arthritis. Lancet, 1, 589.
59. [59] Yoshino, S. & Yoshino, J. (1992), Suppression of chronic antigen-induced arthritis in rats by a monoclonal antibody against the T cell receptor αβ. Cell. Immunol., 144, 382-391.
60. [60] Jung, S., Kramer, S., Schluesener, H.J. et al. (1992), Prevention and therapy of experimental autoimmune neuritis by an antibody against T cell receptors-alpha/beta. J. Immunol., 148, 3768-3775.
61. [61] Zaller, D.M., Osman, G., Kanagawa, O. et al. (1990), Prevention and treatment of murine experimental allergic encephalomyelitis with T cell receptor Vβ-specific antibodies. J. Exp. Med., 171, 1943-1955.
62. [62] Hashim, G.A., Vandenbark, A.A., Galang, A.B. et al. (1990), Antibodies specific for VB8 receptor peptide suppress experimental autoimmune encephalomyelitis. J. Immunol., 144, 4621-4627.
63. [63] Grearing, A.J.H. & Newman, W. (1993), Circulating adhesion molecules in disease. Immunol. Today, 14, 506-512.
64. [64] Jasin, H.E., Lightfoot, E., Davis, L.S. et al. (1992), Amelioration of antigen-induced arthritis in rabbits treated with monoclonal antibodies in leucocytes adhesion molecules. Arthritis Rheum., 35, 541-549.
65. [65] Kavanaugh, A., Nichols, L., Davis, L. et al. (1993), Anti-CD54 (intercellular adhesion molecule-1 ; ICAM-1) monoclonal antibody therapy in refractory rheumatoid arthritis. Arthritis Rheum., 36, S40.
66. [66] Davis, L.S., Kavanaugh, A.F., Nichols, L.A. et al. (1995), Induction of persistent T cell hyporesponsiveness in vivo by monoclonal antibody to ICAM-1 in patients with rheumatoid arthritis. J. Immunol., 154, 3525-3537.
67. [67] Elliott, M.J. & Maini, R.N. (1994), New direction for biological therapy in rheumatoid arthritis. Int. Arch. Allergy Immunol., 104, 112-125.
68. 1 integrin. Nature (Lond.), 356, 63-66.
69. [69] Jerne, N.K. (1974), Towards a network theory of the immune system. Ann. Immunol. (Inst. Pasteur), 125C, 373-382.
70. [70] Lefvert, A.K. & Osterman, P.O. (1993), Newborn infants to myasthenic mothers: a clinical study and an investigation of kinetic and biochemical properties of the acetylcholine receptor antibodies. Neurology, 33, 133-138.
71. [71] Isenberg, D.A., Shoenfeld, Y., Madaio, M. et al. (1984), Measurement of anti-DNA antibody idiotypes to monitor the course of SLE. Lancet, 2, 418-423.
72. [72] Mendlovic, S., Bbrocke, S., Shoenfeld, Y. et al. (1988), Induction of systemic lupus erythematosus-like disease in mice by a common anti-DNA idiotype. Proc. Natl. Acad. Sci. USA 85, 2260-2264.
73. [73] Blank, M., Cohen, J., Toder, V. et al. (1991), Induction of anti-phospholipid syndrome in naive mice with mouse lupus monoclonal and human polyclonal anti-cardiolipin antibodies. Proc. Natl. Acad. Sci. USA, 88, 3069-3073.
74. [74] Bakimer, R., Fishman, P., Blank, M. et al. (1992), Induction of primary antiphospholipid syndrome in mice by immunization with a human monoclonal anticardiolipin antibody (H-3). J. Clin. Invest. 89, 1558-1563.
75. [75] Blank, M., Ben-Bassat, M. & Shoenfeld, Y. (1991), Modulation of SLE induction in naive mice by specific T cells with suppressor activity to pathogenic anti-DNA antibody idiotype. Cell. Immunol., 137, 474-486.
76. 1 mice: Possible role for specific immune suppression. Clin. Exp. Immunol., 58, 293-294.
77. [77] Sasaki, T., Muryoi, T., Takai, O. et al. (1986), Selective elimination of anti-DNA antibody-producing cells by anti-idiotypic antibody conjugated with neocarzinostatin. J. Clin. Invest. 77, 1382-1386.
78. [78] Buskila, D. & Shoenfeld, Y. (1993), From a practical viewpoint - immunomodulation with natural autoanti-idiotypic antibodies: the role of treatment with intravenous immunoglobulins (IVIG), in "Natural autoantibodies" (Shoenfeld Y., Isenberg D.A.), (pp. 303-336). CRC Press, Inc. Boca Raton.
79. [79] Falhaman, CG. (1992), Immunotherapy of rheumatic diseases based on understanding genetic predisposing to the development of these diseases. Rheum. Dis. Clin. North Am., 18, 915-926.
80. [80] Copper, S.M., Sriram, S. & Ranges, G.E. (1988), Suppression to murine collagen induced arthritis with monoclonal anti-Ia antibodies and augmentation with INF gamma. J. Immunol., 141, 1958-1962.
81. [81] Christadoss, P., Lennon, V.A. & David, C. (1979), Genetic control of experimental autoimmune myasthenia gravis in mice-I. Lymphocyte proliferative response to acetylocholine receptors is under H2-linked Ir gene control. J. Immunol., 123, 2540-2545.
82. [82] Waldor, M.K., Sriram, S., McDevitt, H.O. et al. (1983), In vivo therapy with monoclonal anti I-A antibody suppresses immune responses to acetylcholine receptor. Proc. Natl. Acad. Sci. USA, 80, 2713-2717.
83. u1. J. Immunol., 148, 3049-3054.
84. [84] Aharoni, R., Teitelbaum, D., Arnon, R. et al. (1991), Immunomodulation of experimental allergic encephalomyelitis by antibodies to the antigen Ia complex. Nature (Lond.), 351, 147-150.
85. [85] Adelman, N.B., Watling, D.L. & McDevitt, H.O. (1983), Treatment of (NZB X NZW)F1 disease with anti-Ia monoclonal antibodies. J. Exp. Med. 158, 1350-1355.
86. [86] Beisel, K.W., David, C.S., Giraldo, A.A. et al. (1982), Regulation of experimental autoimmune thyroiditis: mapping of susceptibility to the I-A subregion of the mouse H-2. Immunogenetics, 15, 427-430.
87. 4 antibody on development of diabetes in NOD mice. Diabetes, 36, 539-541.
88. [89] Aharoni, R., Teitelbaum, D., Arnon, R. et al. (1991), Immunomodulation of experimental allergic encephalomyelitis by antibodies to the antigen Ia complex. Nature (Lond.), 351, 147-150.
89. [90] Billingham, M.E., Hicks, C. & Carney, S. (1990), Monoclonal antibodies and arthritis. Agents Actions, 29, 77-87.
90. [91] Perosa, F. & Ferrone, S. (1989), Murine anti-idiotypic monoclonal antibodies that bear the internal image of HLA-DR allospecificities. J. Clin. Invest., 84, 907-914.
91. [92] Nisonoff, A. (1991), Idiotypes: concepts and applications. J. Immunol., 147, 2429-2438.
92. [93] Adorini, L. (1993), Selective inhibition of T cell responses by protein and peptide-based immunotherapy. Clin. Exp. Rheumatol., 11, S41-S44.
93. [94] Janeway, C.L. (1989), Immunotherapy by peptides. Nature (Lond.), 341, 482.
94. [95] Guery, J.C., Sette, A., Appela, E. et al. (1995), Constitutive presentation of dominant epitopes from endogenous naturally processed self-beta-2-microglobulin to class-II-restricted T cells leads to self-tolerance. J. Immunol., 154, 545-554.
95. u1. J. Immunol., 148, 3049-3054.
96. [97] Shulman, J. Pierce, M.I. & Lukens, A. (1960), Studies on thrombopoiesis. - I. A factor in normal human plasma required for platelet production. Chronic thrombocytopenia due to its deficiency. Blood, 16, 343-345.
97. [98] Imbach, P., Barandun, S., D'Apuzzo, V. et al. (1981), High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in children. Lancet, 1, 1228-1231.
98. [99] Imbach, P., Berchtold, W., Hirt, A. et al. (1985), Intravenous immunoglobulin versus oral corticosteroids in acute immune thrombocytopenic purpura in childhood. Lancet, 2, 464-468.
99. [100] Zimmerman, R., Kommarel, B., Harenburg, J. et al. (1985), Intravenous IgG for patients with spontaneous inhibitor to factor VIII. Lancet, 1, 273-274.
100. [101] McGuire, W.A., Yang, H.H. & Bruno, E. (1987), Treatment of antibody mediated pure red-cell aplasia with high-dose intravenous gammaglobulin. N. Engl. J. Med., 317, 1004-1008.
101. [102] Pocecco, M., Ventura, A., Tamaro, P. et al. (1986), High-dose IVIG in autoimmune hemolytic anemia. J. Pediatr., 109, 726.
102. [103] Barbui, T., Bassan, R., Viero, P. et al. (1984), Pure white cell aplasia treated by high dose intravenous immunoglobulin. Br. J. Haematol., 58, 556-562.
103. [104] Bussel, J., Lalezari, P. & Fikring, S. (1988), Intravenous treatment with gammaglobulin of autoimmune neutropenia of infancy. J. Pediatr., 112, 298-301.
104. [105] Corvetta, A., Bitta, R.D., Gabrielli, A. et al. (1989), Use of high-dose intravenous immunoglobulin in systemic lupus erythematosus: report of three cases. Clin. Exp. Rheumatol., 7, 295-299.
105. [106] Tomer, Y. & Shoenfeld, Y. (1992), Successful treatment of psychosis secondary to SLE with high dose intravenous immunoglobulin. Clin. Exp. Rheumatol., 10, 391-393.
106. [107] Petersen, H.H., Nielsen, H., Hansen, M. et al. (1990), High-dose immunoglobulin therapy in pericarditis caused by SLE. Scand. J. Rheumatol., 19, 91-93.
107. [108] Corvetta, A., Luchetti, M.M., Pompino, G. et al. (1991), Effect of high-dose intravenous immunoglobulin in rheumatoid arthritis, in "Immunotherapy with intravenous immunoglobulins" (Imbach P., ed.) (pp. 283-295). Academic Press, New York.
108. [109] Becker, H., Mitropoulou, G. & Helmke, K. (1989), Immunomodulating therapy of rheumatoid arthritis by high-dose intravenous immunoglobulin. Klin. Wochenschr., 67, 286-290.
109. [110] Combe, B., Corso, B., Clot, J. et al. (1985), Human placenta-eluted gammaglobulins in immuno-modulating treatment of rheumatoid arthritis. Am. J. Med., 78, 920-928.
110. [111] Silverman, E.D., Laxer, R.M., Greenwald, M. et al. (1990), Intravenous gammaglobulin therapy in systemic juvenile rheumatoid arthritis. Arthritis Rheum., 33, 1015-1022.
111. [112] Lookwood, C.M. (1991), Therapeutic opportunities in systemic vasculitis, in "Immunotherapy with intravenous immunoglobulins" (Imbach, P., ed.) (pp. 297-306). Academic Press, New York.
112. [113] Rossi, F., Jayne, D.R., Lockwood, C.M. et al. (1991), Anti-idiotypes against anti-neutrophil cytoplasmic antigen autoantibodies in normal human polyspecific IgG for therapeutic use and in the remission sera of patients with systemic vasculitis. Clin. Exp. Immunol., 83, 298-303.
113. [114] Parke, A., Maier, D., Hakim, C. et al. (1986), Subclinical autoimmune disease and recurrent spontaneous abortion. J. Rheumatol., 13, 1178-1180.
114. [115] Galli, M., Cortelazzo, S. & Barbui, T. (1991), Intravenous gammaglobulin in patients with antiphospholipid antibodies and thrombocytopenia, in "Immunotherapy with intravenous gammaglobulin." (Imbach P., ed.) (pp. 457-458). Academic Press, New-York.
115. [116] Dalakas, M.R., Illa, I. Dambroisa, Z.M. et al. (1993), A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N. Engl. J. Med., 329, 1993-2000.
116. [117] Panto, F., Giordano, C. & Amato, M.P. (1990), The influence of high-dose intravenous immunoglobulins on immunological and metabolic pattern in newly diagnosed type I diabetic patients. J. Autoimmun., 3, 587-592.
117. [118] Dwyer, J.M. (1992), Manipulating the immune system with immune globulin. N. Engl. J. Med., 326, 107-116.
118. [119] Sahar, E., Murphy, E.G. & Roifman, C.M. (1990), Benefit of intravenously administered immune serum globulin in patients with Guillian-Barré syndrome. J. Pediatr., 116, 141-144.
119. [120] Albama, M., McNamara, M.E., Sokol, M. et al. (1987), Improvement of neurologic function in chronic inflammatory demyelinating polyradiculo-neuropathy following intravenous gammaglobulin infusion. Arch. Neurol., 44, 248-252.
120. [121] Rothfelder, U., Neu, I. & Pelka, R. (1982), Therapie der multiplen Sklerose mit immunoglobulin G. Muench Med. Wochenschr., 124, 74-78.
121. [122] Nydegger, U.R.S.E. (1991), Hypothetic and established action mechanisms of therapy with immunoglobulin G, in "Immunotherapy with intravenous immunoglobulins" (Imbach, P., ed.) (pp. 27-36). Academic Press, New York.
122. [123] Hilgartner, M.W. & Bussel, J. (1987), Use of intravenous gammaglobulin for the treatment of autoimmune neutropenia of childhood and autoimmune hemolytic anemia. Am. J. Med., 83, 25-29.
123. [124] Kulicks, J., Rajnavolgy, I.E., Fust, G. et al. (1983), Interaction of C3 and C3b with immunoglobulin G. Mol. Immunol., 20, 805-810.
124. [125] Engelhard, D., Waner, J.L., Kapoor, N. et al. (1986), Effect of intravenous immune globulin on natural killer cell activity: possible association with autoimmune neutropenia and idiopathic thrombocytopenia. J. Pediatr., 108, 77-81.
125. [126] Mannhalter, J.W., Ahmad, R., Wolf, H.M. et al. (1987), Effect of polymeric IgG on human monocyte functions. Int. Arch. Allergy Appl. Immunol., 82, 159-167.
126. [127] Fischer, S. & Weber, P.C. (1984), Prostaglandin I3 is formed in vivo in man after dietary eicosapentaenoic acid. Nature (Lond.), 307, 165-168.
127. [128] Lee, T.H., Hoover, R.L., Williams, J.D. et al. (1985), Effect of dietary enrichment with eicosapentaenoic and decosahexaenoic acids on in vitro neutrophil and monocyte leukotriene generation and neutrophil function. N. Engl. J. Med. 312, 1217-1224.
128. [129] Kremer, J.M., Lawence, D.A., Jubiz, W. et al. (1990), Dietary fish oil and olive oil supplementation in patients with rheumatoid arthritis. Arthritis Rheum, 33, 810-819.
129. [130] Bittiner, S.B., Cartwright, I., Tucker, W.G.F. et al. (1988), A double-blind, randomized, placebo controlled trial of fish oild in psoriasis. Lancet, 1, 378-380.
130. [131] Walton, A.J.E., Spaith, M.C., Cumberland, A.G. et al. (1991), Dietary fish and the severity of symptoms in patients with systemic lupus erythematosus. Ann. Rheum. Dis., 50, 463-466.
131. [132] Lai, L.T., Naiki, M., Yoshida, S.H. et al. (1994), Dietary Platycladus orientalis seed oil suppresses anti-erythrocyte autoantibodies and prolongs survival of NZB mice. Clin. Immunol. Immunopathol., 71, 293-302.
132. [133] Fashim, A.T., Abed-el Fattah, A.A., Agha, A.M. et al. (1995), Effect of pumpkin-seed oil on the level of free radical scavengers induced during adjuvant-arthritis rats. Pharmacol. Res., 31, 73-79.
133. [134] Leventhal, L.J., Boyce, E.G. & Zurier, R.B. (1994), Treatment of rheumatoid arthritis with blackcurrant seed oil. Br. J. Rheumatol., 33, 847-852.
134. [135] Franceschi, R.T., Simpson, R.U. & DeLuca, H.F. (1981), Binding protein for vitamin D metabolites; serum carriers and intracellular receptors. Arch. Biochem. Biophys., 210, 1-13.
135. [136] Halla, A.K., Amento, E.P., Clemens, T.L. et al. (1983), Specific high affinity receptors for 1.25 dihydroxy-vitamin D3 in human peripheral blood mononuclear cells: presence in monocytes and induction in T lymphocytes following activation. J. Clin. Endocrinol. Metab., 57, 1308-1310.
136. [137] Rigby, W.F.C., Stacy, T. & Fanger, M.W. (1984), Inhibition of T lymphocyte mitogenesis by 1,25-dihydroxyvitamin D3 (calcitriol). J. Clin. Invest., 74, 1451-1455.
137. [138] Rigby, W.F.C., Denome, S. & Fanger, M.W. (1987), Regulation of lymphokine production and human T lymphocyte activation by 1.25-dihydroxyvitamin D3. Specific inhibition at the level of messenger RNA. J. Clin Invest., 79, 1659-1664.
138. [139] Gepner, P., Amor, B. & Fournier, C. (1989), 1.25-dihydroxyvitamin D3 potentiates the in vitro inhibitory effects of cyclosporin A on T cells from rheumatoid arthritis patients. Arthritis Rheum., 32, 31-36.
139. [140] Lemire, J.M., Ince, A. & Trakashima, M. (1992), 1.25-Dihydroxyvitamin D3 attenuates the expression of experimental murine lupus of MRL/I mice. Autoimmunity, 12, 143-148.
140. [141] Fournier, C., Gepner, P., Sadouk, M.B. et al. (1990), In vivo beneficial effects of cyclosporin A and 1.25-dihydroxyvitamin D3 on the induction of experimental autoimmune thyroiditis. Clin. Immunol. Immunopathol., 54, 53-63.
141. [142] Lassmann, H., Suchanek, G., Kitz, K., Stemberger, H. et al. (1984), Antibodies in the pathogenesis of demyelination in chronic relapsing EAE, in "Experimental allergic encephalomyelitis: a useful model for multiple sclerosis." (Alvord E.D.C., Kies, M.W., and Suckling, A.J., Ed.) (pp. 165-170). Alan R. Liss, Inc. New York.
142. [143] Lemire, J.M., Archer, D.C., Beck, L. et al. (1995), Immunosuppressive actions of 1,25-dihydroxyvitamin D3: preferential inhibition of Th1 functions. J. Nutr., 125, 1704S-1708S.
143. [144] Sperling, R.I. (1989), Diet therapy in rheumatoid arthritis. Curr. Opin. Rheumatol., 1, 33-38.
144. [145] Thompson, H.S.G. & Staines, N.A. (1986), Gastric administration of type II collagen delays the onset of severity of collagen-induced arthritis in rats. Clin. Exp. Immunol., 64, 581-586.
145. + lymphocytes. J. Immunol., 142, 748-752.
146. [147] Zhang, J.A., Davidson, L., Eisenbarth, G. et al. (1991), Suppression of diabetes in NOD mice by oral administration of porcine insulin. Proc. Natl. Acad. Sci. USA, 88, 10252-10256.
147. [148] Miller A., Lider, O., Roberts, A.B. et al (1992), Suppressor T cells generated by oral tolerization to myelin basic protein suppress both in vitro and in vivo immune responses by the release of TGF-β following antigen specific triggering. Proc. Natl. Acad. Sci. USA, 89, 7762-7766.
148. [149] Melamed, D. & Friedman, A. (1991), Direct evidence for anergy in T lymphocyte tolerized by oral administration of ovalbumun. - III. Evidence for clonal anergy. Eur. J. Immunol., 22, 935-942.
149. [150] Thomson, A.W. & Forrester, J.V. (1994), Therapeutic advances in immunosuppression. Clin. Exp. Immunol., 98, 351-357.
150. [151] Trentham, D.E., Dynesius-Trentham, R.A., Orav, E.J. et al. (1993), Effects of oral administration of type II collagen on rheumatoid arthritis. Science, 261, 1669-1670.